- Home
- BL vs SRRK Comparison
BL vs SRRK Comparison
Compare BL & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BL
- SRRK
- Stock Information
- Founded
- BL 2001
- SRRK 2012
- Country
- BL United States
- SRRK United States
- Employees
- BL N/A
- SRRK N/A
- Industry
- BL Computer Software: Prepackaged Software
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BL Technology
- SRRK Health Care
- Exchange
- BL Nasdaq
- SRRK Nasdaq
- Market Cap
- BL 3.5B
- SRRK 3.2B
- IPO Year
- BL 2016
- SRRK 2018
- Fundamental
- Price
- BL $56.00
- SRRK $38.95
- Analyst Decision
- BL Buy
- SRRK Strong Buy
- Analyst Count
- BL 13
- SRRK 7
- Target Price
- BL $58.38
- SRRK $42.17
- AVG Volume (30 Days)
- BL 583.7K
- SRRK 1.2M
- Earning Date
- BL 08-05-2025
- SRRK 08-06-2025
- Dividend Yield
- BL N/A
- SRRK N/A
- EPS Growth
- BL 28.07
- SRRK N/A
- EPS
- BL 1.41
- SRRK N/A
- Revenue
- BL $662,806,000.00
- SRRK N/A
- Revenue This Year
- BL $10.09
- SRRK N/A
- Revenue Next Year
- BL $8.69
- SRRK $1,960.31
- P/E Ratio
- BL $39.72
- SRRK N/A
- Revenue Growth
- BL 8.93
- SRRK N/A
- 52 Week Low
- BL $40.82
- SRRK $6.76
- 52 Week High
- BL $66.25
- SRRK $46.98
- Technical
- Relative Strength Index (RSI)
- BL 50.12
- SRRK 55.72
- Support Level
- BL $53.40
- SRRK $36.91
- Resistance Level
- BL $57.99
- SRRK $41.33
- Average True Range (ATR)
- BL 1.22
- SRRK 1.84
- MACD
- BL -0.00
- SRRK -0.12
- Stochastic Oscillator
- BL 56.57
- SRRK 51.57
About BL BlackLine Inc.
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.